In the past week, NMRA stock has gone down by -4.98%, with a monthly decline of -3.05% and a quarterly plunge of -83.32%. The volatility ratio for the week is 7.02%, and the volatility levels for the last 30 days are 9.60% for Neumora Therapeutics Inc. The simple moving average for the past 20 days is -10.62% for NMRA’s stock, with a -81.27% simple moving average for the past 200 days.
Is It Worth Investing in Neumora Therapeutics Inc (NASDAQ: NMRA) Right Now?
Moreover, the 36-month beta value for NMRA is 2.37. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for NMRA is 55.17M and currently, short sellers hold a 19.99% of that float. On February 05, 2025, NMRA’s average trading volume was 3.02M shares.
NMRA) stock’s latest price update
Neumora Therapeutics Inc (NASDAQ: NMRA)’s stock price has soared by 2.69 in relation to previous closing price of 1.86. Nevertheless, the company has seen a loss of -4.98% in its stock price over the last five trading days. accessnewswire.com reported 2025-02-04 that NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Neumora Therapeutics, Inc. (“Neumora Therapeutics, Inc.”) (NASDAQ:NMRA) concerning possible violations of federal securities laws. On January 2, 2025, Neumora announced its experimental depression treatment failed in the first of three studies planned by the biotech company.
Analysts’ Opinion of NMRA
Many brokerage firms have already submitted their reports for NMRA stocks, with RBC Capital Mkts repeating the rating for NMRA by listing it as a “Sector Perform.” The predicted price for NMRA in the upcoming period, according to RBC Capital Mkts is $4 based on the research report published on January 02, 2025 of the current year 2025.
JP Morgan, on the other hand, stated in their research note that they expect to see NMRA reach a price target of $15, previously predicting the price at $18. The rating they have provided for NMRA stocks is “Neutral” according to the report published on November 05th, 2024.
H.C. Wainwright gave a rating of “Buy” to NMRA, setting the target price at $30 in the report published on October 01st of the previous year.
NMRA Trading at -71.57% from the 50-Day Moving Average
After a stumble in the market that brought NMRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.90% of loss for the given period.
Volatility was left at 9.60%, however, over the last 30 days, the volatility rate increased by 7.02%, as shares sank -11.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -80.63% lower at present.
During the last 5 trading sessions, NMRA fell by -4.98%, which changed the moving average for the period of 200-days by -81.76% in comparison to the 20-day moving average, which settled at $2.1370. In addition, Neumora Therapeutics Inc saw -81.98% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NMRA starting from Fust Matthew K, who sale 14,049 shares at the price of $17.03 back on Oct 18 ’24. After this action, Fust Matthew K now owns 20,100 shares of Neumora Therapeutics Inc, valued at $239,319 using the latest closing price.
Fust Matthew K, the Director of Neumora Therapeutics Inc, sale 7,739 shares at $17.01 during a trade that took place back on Oct 17 ’24, which means that Fust Matthew K is holding 20,100 shares at $131,643 based on the most recent closing price.
Stock Fundamentals for NMRA
The total capital return value is set at -0.98. Equity return is now at value -70.48, with -65.46 for asset returns.
Based on Neumora Therapeutics Inc (NMRA), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -67.04.
Currently, EBITDA for the company is -187.53 million with net debt to EBITDA at 0.91. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.98.
Conclusion
To wrap up, the performance of Neumora Therapeutics Inc (NMRA) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
